Artbio, a radiopharmaceutical company developing targeted alpha radioligand therapies, and Nucleus RadioPharma are entering a strategic manufacturing and supply agreement.
Under the deal, Nucleus will use Artbio’s AlphaDirect 212Pb isolation technology to manufacture Artbio’s lead-212 (Pb-212) radiolabeled therapies, which will be used for phase I and II clinical trials of Artbio's AB001 lead prostate cancer treatment candidate. This agreement will enable the supply and manufacturing of alpha radioligand therapies from Nucleus’ facility in Rochester, MN, for patients living in the Northern and Midwest U.S., the companies said.
Pb-212 is an alpha-emitting radioisotope that is being investigated for its potential applications in therapeutic medicine, particularly in targeted alpha radioligand therapy due to the radioisotope’s short half-life and other properties, according to the firms.
